AI brief of an SEC Form 8-K · CSX (CSX)

CSX Q4 2025 EPS rises to $0.39 as revenue falls 1% to $3.51 billion

Mixed Impact 3 of 5 earnings Written later

CSX reported fourth quarter 2025 revenue of $3.51 billion, down 1% from a year earlier, as lower merchandise volume and reduced export coal revenue offset higher pricing. Net earnings were $720 million, or $0.39 per share, versus $733 million, or $0.38 per share, a year earlier, but the prior-year figure excluded a goodwill impairment, and the quarter included about $50 million in severance and technology costs. For the full year, EPS fell 14% to $1.54 and revenue fell 3% to $14.09 billion, which matters to shareholders because the earnings trend weakened over the year.

Key points

  • Q4 2025 revenue was $3.51 billion, down 1% year over year; operating margin was 31.6% versus 31.3% a year earlier.
  • Q4 2025 EPS was $0.39 versus $0.38 in Q4 2024; prior-year adjusted EPS was $0.42 excluding a goodwill impairment.
  • Full-year 2025 EPS was $1.54 versus $1.79 in 2024, down 14%; full-year net earnings were $2.89 billion versus $3.47 billion.
  • Full-year 2025 results include a $164 million goodwill impairment charge recorded in the third quarter.

The filing

CompanyCSX (CSX)
Form8-K, current report
Filed with the SECJan 22, 2026, 4:01 PM ET
Accession number0000277948-26-000003

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:21 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 22, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.